This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|October 15, 2020
- BioPharm International-10-15-2020
- Volume 2020 eBook
- Issue 3
Viewpoint: Precompetitive Collaboration Drives Pharma Industry Innovation
The IQ Consortium marks a decade of impactful innovation of collaboration through a network of pharmaceutical companies driving change for the bio/pharmaceutical industry.
Advertisement
Pharmaceutical development is a long, risky, and expensive process. In this highly competitive market, pharmaceutical companies are under constant pressure to deliver innovation via new therapeutics, new technology, and improved efficiency and effectiveness (1). Precompetitive collaboration is recognized as a mechanism to enhance efficiency, mitigate risks, and share costs that can benefit industry, academia, and government agencies. For the purposes of this viewpoint, “precompetitive collaboration” may be defined as collaborations between pharmaceutical companies and third parties to produce an efficiency-enhancing advancement or refinement that will be made broadly available to the public (i.e., publication, commercialization of a new product).
Article Details
BioPharm International
eBook: Regulatory Sourcebook, October 2020
October 2020
Pages: 45–49
Citation
When referring to this article, please cite it as M. M. Faul et al.,“Viewpoint: Precompetitive Collaboration Drives Pharma Industry Innovation," BioPharm International Regulatory Sourcebook eBook (October 2020).
Articles in this issue
about 6 years ago
Bio/Pharma Industry Works Overtime to Find COVID-19 Therapiesabout 6 years ago
GMPs Guide COVID-19 Vaccine Manufacturingabout 6 years ago
Viral Vector API Characterization of Product-Related Impuritiesabout 6 years ago
Tackling Cybersecurity Challenges in Legacy Systemsabout 6 years ago
Due Diligence Assessment of CMC Activitiesabout 6 years ago
Strong Quality Culture: A How-To for Busy Managersabout 6 years ago
Resources, Guidelines, and Guidance Documentsabout 6 years ago
Regulatory and Standard Setting OrganizationsAdvertisement
Related to this article
CAR-T transformed blood cancer care, but solid and brain tumors demand different delivery, manufacturing, and safety strategies to work.
Johnson & Johnson's amivantamab (Rybrevant Faspro) won accelerated FDA approval for pretreated recurrent head and neck cancer.
FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
Akeso won NMPA priority review for ivonescimab plus chemotherapy in first-line biliary tract cancer after a phase 3 win over durvalumab plus chemo.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
argenx Agrees to Buy Unnatural Products in Up to $1.15 Billion Deal
3
J&J’s Dual-Antigen Bispecific Regimen Achieves 73% PSA Response in Advanced Prostate Cancer
4
Janux’s JANX011 T-Cell Engager Shows Deep B-Cell Depletion in Phase 1 Healthy Volunteer Study
5